Madison-made technology to treat diabetic foot ulcers

Photo courtesy MGN Online Image Id: 353462 11/22/2016
By  | 

MADISON, Wis. (AP) -- Human tests have begun on a wound-healing skin tissue developed in Madison.

The Wisconsin State Journal reports that ExpressGraft-C9T1 is being tested on up to six patients with diabetic foot ulcers.

The technology is being developed by Stratatech, which is now owned by the British pharmaceutical company Mallinckrodt. The technology is a genetically engineered, antimicrobial human skin substitute.

Lynn Allen-Hoffmann was the founder and CEO of Stratatech and is now senior vice president of regenerative medicine at Mallinckrodt. She says the tissue may be able to help patients with chronic wounds that are difficult to heal.

The study is expected to be completed in May 2019. If successful, the product would need two additional rounds of testing before Mallinckrodt could seek approval from the U.S. Food and Drug Administration.

The comment sections of our web set are designed for thoughtful, intelligent conversation and debate. We want to hear from the viewers but we are not obligated to post comments we feel inappropriate or violate our guidelines. Here are some of the criteria you should follow when posting comments:

Comments cannot be profane or vulgar. Children and families visit this site. We will delete comments that use profanity or cross the lines of good taste.

We will delete all comments using hate speech. Slurs, stereotypes and violent talk aren’t welcome on our web site.

Comments should not attack other readers personally.

We will delete comments we deem offensive, in bad taste, or out of bounds. We are not obligated to post comments that are rude or insensitive.

We do not edit user-submitted comments.

As a host WEAU 13 News welcomes a wide spectrum of opinions. However, we have a responsibility to all our readers to try to keep our comment section fair and decent. For that reason WEAU 13 News reserves the right to not post or to remove any comment.
powered by Disqus